Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and phosphorylcholine

sorafenib has been researched along with phosphorylcholine in 6 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(phosphorylcholine)		Trials
(phosphorylcholine)		Recent Studies (post-2010) (phosphorylcholine)
6,5207305,2515,3082551,893

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Samlowski, W; Vogelzang, NJ; Weissman, A1
Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R1
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D1
Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S1
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW1
Duan, X; Wang, Z; Zhang, Y; Zhao, K; Zhao, Y1

Trials

1 trial(s) available for sorafenib and phosphorylcholine

ArticleYear
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-15, Volume: 20, Issue:22

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult

2014

Other Studies

5 other study(ies) available for sorafenib and phosphorylcholine

ArticleYear
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors

2009
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Leukemia, 2013, Volume: 27, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2013
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    British journal of haematology, 2013, Volume: 161, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured

2013
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53

2015
Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
    Pharmaceutical research, 2019, Aug-08, Volume: 36, Issue:10

    Topics: Animals; Antagomirs; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cell Survival; Cholesterol; Drug Synergism; Forkhead Box Protein O1; Glypicans; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Lipids; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanoparticles; Phosphorylcholine; Polyethylene Glycols; PPAR gamma; Sorafenib

2019